The European Medicines Agency's Committee for Medicinal Products for Human Use recommended that Pfizer's Bosulif, or bosutinib, be approved to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia who didn't respond to or can't tolerate other treatments. The drug, a tyrosine kinase inhibitor, was cleared by the FDA in September.

Related Summaries